Chosa Oncology

Stockholm, Sweden· Est. 2018

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Chosa Oncology is a private, pre-revenue diagnostics company focused on bringing tumor biology into platinum chemotherapy treatment decisions. Its core technology is the Platin-DRP®, a gene expression-based biomarker test designed to identify patients with solid tumors who are most likely to benefit from cisplatin or carboplatin. The company has presented multiple clinical validations in non-small cell lung cancer (NSCLC) and metastatic breast cancer and is positioning its test as a decision-support tool to improve precision in using these cornerstone therapies. Chosa is based in Stockholm, Sweden, and is led by a team with support from key opinion leaders in oncology.

OncologyLung CancerBreast CancerBladder CancerEndometrial Cancer

Technology Platform

Platin-DRP®: A gene expression-based biomarker platform that analyzes RNA from tumor biopsies to generate a predictive score for patient response to platinum-based chemotherapies (cisplatin/carboplatin).

Opportunities

The ubiquitous use of platinum chemotherapies across multiple solid tumors creates a vast addressable market for a predictive test.

The test also presents an opportunity to serve pharmaceutical companies by enriching clinical trial populations for platinum-based regimens, improving trial efficiency.

Risk Factors

Key risks include the failure of prospective clinical trials to validate the test's utility in improving patient outcomes, challenges in obtaining regulatory approval and securing payer reimbursement, and competition from other predictive biomarkers or diagnostic technologies.

Competitive Landscape

Chosa competes in the predictive oncology diagnostics space, which includes other multi-gene signature tests and emerging AI-based tools. Its direct focus on platinum chemotherapy response is niche, but it faces competition from broader prognostic tests and the general challenge of changing clinical practice.